Mucinex and Exjade drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Mucinex (guaifenesin) and Exjade (deferasirox). Common drug interactions include asthenia among females and haemoglobin decreased among males.
The phase IV clinical study analyzes what interactions people have when they take Mucinex and Exjade. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.
What is Mucinex?
Mucinex has active ingredients of guaifenesin. It is often used in cough. eHealthMe is studying from 29,749 Mucinex users. Check the latest studies of Mucinex.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
35 people who take Mucinex and Exjade together, and have interactions are studied.

What are the common drug interactions of Mucinex and Exjade, by gender? *:
female:
- Asthenia (weakness)
- Death
- Abdominal pain
- Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
- Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
- Gastrointestinal infection (infection of stomach and intestine)
- Haemoglobin decreased
- Intestinal haemorrhage (bleeding from intestine)
- Pancreatolithiasis (presence of calculi or stones in the pancreas or pancreatic duct)
- Pneumonia
male:
- Haemoglobin decreased
- Blood urea increased
- Blood creatinine increased
- Renal failure (kidney dysfunction)
- Cardiac failure congestive
- Red blood cell count decreased
- Abdominal pain
- Acute myocardial infarction (acute heart attack)
- Alanine aminotransferase increased
- Dyspnoea (difficult or laboured respiration)
What are the common drug interactions of Mucinex and Exjade, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
- Abdominal pain upper
- Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
- Chest discomfort
- Eye colour change
- Eye disorder
- Eye pruritus (eye itching)
- Eye swelling
- Headache (pain in head)
- Pain
20-29:
- Anisocytosis (patient's red blood cells are of unequal size)
- Dyspnoea (difficult or laboured respiration)
- Fatigue (feeling of tiredness)
- Haematocrit decreased
- Haemoglobin decreased
- Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
- Haptoglobin decreased
- Lymphocyte percentage increased
- Mean cell haemoglobin concentration decreased (less concentration of haemoglobin in a given volume of packed red blood cells)
- Mean cell haemoglobin decreased (less than normal haemoglobin per red blood cell in a sample of blood)
30-39:
- Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)
40-49:
- Renal failure (kidney dysfunction)
- Ascites (accumulation of fluid in the abdominal cavity)
- Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
- Diarrhoea
- Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
- Liver disorder (liver diseases)
- Swelling face
- Weight increased
- Pulmonary air leakage
50-59:
- Rash generalised (rash on most of body parts)
- Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
- Hypermagnesaemia (an electrolyte disturbance in which there is an abnormally elevated level of magnesium in the blood)
- Renal impairment (severely reduced kidney function)
60+:
- Diarrhoea
- Haemoglobin decreased
- Anaemia (lack of blood)
- Visual impairment
- Cardiac failure congestive
- Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
- Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
- Fatigue (feeling of tiredness)
- Gastrointestinal infection (infection of stomach and intestine)
- Intestinal haemorrhage (bleeding from intestine)
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 6 people, 17.14%
- Hypersensitivity: 4 people, 11.43%
- Nausea (feeling of having an urge to vomit): 4 people, 11.43%
- Iron Metabolism Disorder: 4 people, 11.43%
- Haemochromatosis (body to absorb more iron than usual from food): 3 people, 8.57%
- Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 3 people, 8.57%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 5.71%
- Depression: 2 people, 5.71%
- Diabetes: 2 people, 5.71%
- Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 5.71%
* Approximation only. Some reports may have incomplete information.
Do you take Mucinex and Exjade?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Mucinex and Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Mucinex:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Mucinex and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exjade and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on guaifenesin and deferasirox (the active ingredients of Mucinex and Exjade, respectively), and Mucinex and Exjade (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Cefobid cause Chest Pain? - 6 seconds ago
- Drug interactions of Erlotinib Hydrochloride and Effexor - 8 seconds ago
- Could Temazepam cause Pulpitis Dental? - 13 seconds ago
- Could Cartia Xt cause White Blood Cell Count Decreased? - 27 seconds ago
- Could Finasteride cause Venous Thrombosis? - 30 seconds ago
- Drug interactions of Cefdinir and Uptravi - 32 seconds ago
- Drug interactions of Combipatch and Aspirin - 34 seconds ago
- Could Tegsedi cause Dizziness? - 35 seconds ago
- Could Spironolactone cause Penile Oedema? - 38 seconds ago
- Drug interactions of Sandostatin and Pentasa - 38 seconds ago